{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Chapel+Hill&page=5&state=North+Carolina", "query": { "state": "North Carolina", "city": "Chapel Hill", "page": 5 }, "page_size": 10 }, "pagination": { "page": 5, "page_size": 10, "total_count": 1321, "total_pages": 133, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Chapel+Hill&page=6&state=North+Carolina&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Chapel+Hill&page=4&state=North+Carolina&page_size=10" }, "source": "local", "last_synced_at": "2026-10-30T19:03:51.017Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03739814", "title": "Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative", "Recurrent B Acute Lymphoblastic Leukemia", "Refractory B Acute Lymphoblastic Leukemia" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Blinatumomab", "type": "BIOLOGICAL" }, { "name": "Bone Marrow Aspiration", "type": "PROCEDURE" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" }, { "name": "Inotuzumab Ozogamicin", "type": "BIOLOGICAL" }, { "name": "Lumbar Puncture", "type": "PROCEDURE" }, { "name": "Ponatinib", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 84, "start_date": "2019-05-08", "completion_date": "2027-02-01", "has_results": false, "last_update_posted_date": "2026-10-28", "last_synced_at": "2026-10-29T22:50:26.818Z", "location_count": 283, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Kingman, Arizona + 175 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT03739814" }, { "nct_id": "NCT03072927", "title": "MILD® Percutaneous Image-Guided Lumbar Decompression: A Medicare Claims Study", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Lumbar Spinal Stenosis" ], "interventions": [ { "name": "Interspinous Process Decompression", "type": "DEVICE" }, { "name": "MILD", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Stryker Instruments", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 8000, "start_date": "2017-03-10", "completion_date": "2026-12", "has_results": false, "last_update_posted_date": "2026-10-28", "last_synced_at": "2026-10-28T15:40:16.704Z", "location_count": 2384, "location_summary": "Athens, Alabama • Bay Minette, Alabama • Birmingham, Alabama + 1286 more", "locations": [ { "city": "Athens", "state": "Alabama" }, { "city": "Bay Minette", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT03072927" }, { "nct_id": "NCT01137643", "title": "Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Chronic Myeloproliferative Disorders", "Leukemia", "Lymphoma", "Lymphoproliferative Disorder", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes", "Myelodysplastic/Myeloproliferative Neoplasms", "Nonmalignant Neoplasm" ], "interventions": [ { "name": "biologic sample preservation procedure", "type": "OTHER" }, { "name": "cytology specimen collection procedure", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "UNC Lineberger Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 15000, "start_date": "2009-07", "completion_date": "2040-07", "has_results": false, "last_update_posted_date": "2026-10-28", "last_synced_at": "2026-10-29T21:55:52.652Z", "location_count": 1, "location_summary": "Chapel Hill, North Carolina", "locations": [ { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT01137643" }, { "nct_id": "NCT07012395", "title": "A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colitis", "Colitis, Ulcerative", "Inflammatory Bowel Diseases", "Ulcerative Colitis" ], "interventions": [ { "name": "Placebo", "type": "OTHER" }, { "name": "SPY001", "type": "DRUG" }, { "name": "SPY002", "type": "DRUG" }, { "name": "SPY003", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "Spyre Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 645, "start_date": "2025-05-27", "completion_date": "2028-03", "has_results": false, "last_update_posted_date": "2026-10-27", "last_synced_at": "2026-10-28T15:24:32.085Z", "location_count": 27, "location_summary": "Canoga Park, California • La Jolla, California • Lancaster, California + 24 more", "locations": [ { "city": "Canoga Park", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Lancaster", "state": "California" }, { "city": "Colorado Springs", "state": "Colorado" }, { "city": "Kissimmee", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07012395" }, { "nct_id": "NCT06820463", "title": "A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Colorectal Cancer" ], "interventions": [ { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Panitumumab", "type": "DRUG" }, { "name": "Telisotuzumab Adizutecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 390, "start_date": "2025-04-24", "completion_date": "2028-04", "has_results": false, "last_update_posted_date": "2026-10-27", "last_synced_at": "2026-10-30T19:03:51.017Z", "location_count": 17, "location_summary": "Duarte, California • Santa Monica, California • New Haven, Connecticut + 14 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Orlando", "state": "Florida" }, { "city": "Marietta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT06820463" }, { "nct_id": "NCT06559150", "title": "A Phase II Study of Ensifentrine in Non-Cystic Fibrosis Bronchiectasis", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-cystic Fibrosis Bronchiectasis" ], "interventions": [ { "name": "Nebulized Ensifentrine Suspension; 3 mg", "type": "DRUG" }, { "name": "Nebulized Placebo Solution", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 284, "start_date": "2024-09-11", "completion_date": "2027-09-24", "has_results": false, "last_update_posted_date": "2026-10-27", "last_synced_at": "2026-10-27T23:06:45.254Z", "location_count": 29, "location_summary": "Birmingham, Alabama • Los Angeles, California • Sacramento, California + 26 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT06559150" }, { "nct_id": "NCT06468202", "title": "Effectiveness of Two Aspirin Doses for Prevention of Hypertensive Disorders of Pregnancy: ASPIRIN TRIAL", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Gestational Hypertension", "Hypertensive Disorders of Pregnancy", "Preeclampsia" ], "interventions": [ { "name": "Aspirin 162 mg", "type": "DRUG" }, { "name": "Aspirin 81 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ohio State University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "14 Years", "maximum_age": "35 Years", "sex": "FEMALE", "summary": "14 Years to 35 Years · Female only" }, "enrollment_count": 10742, "start_date": "2024-10-18", "completion_date": "2030-02-01", "has_results": false, "last_update_posted_date": "2026-10-27", "last_synced_at": "2026-10-28T03:29:17.181Z", "location_count": 20, "location_summary": "Birmingham, Alabama • Los Angeles, California • San Francisco, California + 16 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "New Orleans", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT06468202" }, { "nct_id": "NCT06317662", "title": "Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Leukemia of Ambiguous Lineage", "B Acute Lymphoblastic Leukemia" ], "interventions": [ { "name": "Asparaginase Erwinia chrysanthemi", "type": "DRUG" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Blinatumomab", "type": "BIOLOGICAL" }, { "name": "Bone Marrow Aspiration", "type": "PROCEDURE" }, { "name": "Calaspargase Pegol", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Daunorubicin", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "FDG-Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Levoleucovorin", "type": "DRUG" }, { "name": "Lumbar Puncture", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Mercaptopurine", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Methylprednisolone", "type": "DRUG" }, { "name": "Multigated Acquisition Scan", "type": "PROCEDURE" }, { "name": "Prednisolone", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Therapeutic Hydrocortisone", "type": "DRUG" }, { "name": "Thioguanine", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "365 Days", "sex": "ALL", "summary": "Up to 365 Days" }, "enrollment_count": 153, "start_date": "2025-06-05", "completion_date": "2028-12-31", "has_results": false, "last_update_posted_date": "2026-10-27", "last_synced_at": "2026-10-28T00:09:01.313Z", "location_count": 116, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 100 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Loma Linda", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06317662" }, { "nct_id": "NCT06124157", "title": "A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "B Acute Lymphoblastic Leukemia" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Blinatumomab", "type": "BIOLOGICAL" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" }, { "name": "Calaspargase Pegol", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Dasatinib", "type": "DRUG" }, { "name": "Daunorubicin", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Imatinib", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Mercaptopurine", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Multigated Acquisition Scan", "type": "PROCEDURE" }, { "name": "Pegaspargase", "type": "DRUG" }, { "name": "Prednisolone", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Radiation Therapy", "type": "RADIATION" }, { "name": "Thioguanine", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL", "DRUG", "RADIATION" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "366 Days", "maximum_age": "46 Years", "sex": "ALL", "summary": "366 Days to 46 Years" }, "enrollment_count": 222, "start_date": "2025-05-30", "completion_date": "2030-12-01", "has_results": false, "last_update_posted_date": "2026-10-27", "last_synced_at": "2026-10-27T14:15:50.036Z", "location_count": 145, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 121 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Downey", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06124157" }, { "nct_id": "NCT01193088", "title": "Genetics of Charcot Marie Tooth (CMT) - Modifiers of CMT1A, New Causes of CMT2", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Charcot-Marie-Tooth Disease, Type Ia (Disorder)", "HMSN" ], "interventions": [], "intervention_types": [], "sponsor": "University of Iowa", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 1050, "start_date": "2010-05", "completion_date": "2030-12", "has_results": false, "last_update_posted_date": "2026-10-27", "last_synced_at": "2026-10-27T15:01:21.665Z", "location_count": 18, "location_summary": "Los Angeles, California • Palo Alto, California • Aurora, Colorado + 14 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Hartford", "state": "Connecticut" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01193088" } ] }